Skip to main navigation
Molecular Partners

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • Email Alerts
      • Contact IR

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • « Back
    • Overview
    • News & Events
      • « Back
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • « Back
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • « Back
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • « Back
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • « Back
      • Email Alerts
      • Contact IR

Investors

Investors

SHARE PRICE

> View All Stock

  • Detailed Share Information
Latest News
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

> View All News

  • All News
Upcoming Events
More events are coming soon.

> View All Events

  • All Events
Latest Presentation
May 26, 2023
RBC Healthcare Conference Presentation
March 9, 2023
Full-Year Earnings 2022 Presentation
January 12, 2023
J.P. Morgan Healthcare Conference Presentation

> View All Presentations

  • All Presentations
Latest Financial Documents
April 19, 2023
Molecular Partners statement regarding Passive Foreign Investment Company status
March 9, 2023
Annual Report FY2022
October 27, 2022
Q3 2022 Financial Statement

> View All Reports

  • All Annual Report
Seth Lewis

Seth Lewis,
SVP Investor Relations and Strategy

Contact Seth

STAY INFORMED

Subscribe to email alerts of your choosing

SUBSCRIBE

Institutional investors:

  REQUEST 1-1 / CALL

powered by schedulR

> Footer Menu

  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

> Footer Social

© 2023 Molecular Partners.